Cargando…

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

BACKGROUND: Because of the rapid change in economic development and lifestyle in China, and the ageing population, concerns have grown that chronic obstructive pulmonary disease (COPD) could become epidemic. An up-to-date nationwide estimation of COPD prevalence in China is needed. METHODS: We did a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Liwen, Gao, Pei, Bao, Heling, Tang, Xun, Wang, Baohua, Feng, Yajing, Cong, Shu, Juan, Juan, Fan, Jing, Lu, Ke, Wang, Ning, Hu, Yonghua, Wang, Linhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185405/
https://www.ncbi.nlm.nih.gov/pubmed/29650407
http://dx.doi.org/10.1016/S2213-2600(18)30103-6
_version_ 1783526753362247680
author Fang, Liwen
Gao, Pei
Bao, Heling
Tang, Xun
Wang, Baohua
Feng, Yajing
Cong, Shu
Juan, Juan
Fan, Jing
Lu, Ke
Wang, Ning
Hu, Yonghua
Wang, Linhong
author_facet Fang, Liwen
Gao, Pei
Bao, Heling
Tang, Xun
Wang, Baohua
Feng, Yajing
Cong, Shu
Juan, Juan
Fan, Jing
Lu, Ke
Wang, Ning
Hu, Yonghua
Wang, Linhong
author_sort Fang, Liwen
collection PubMed
description BACKGROUND: Because of the rapid change in economic development and lifestyle in China, and the ageing population, concerns have grown that chronic obstructive pulmonary disease (COPD) could become epidemic. An up-to-date nationwide estimation of COPD prevalence in China is needed. METHODS: We did a cross-sectional survey of a nationally representative sample of individuals from mainland China aged 40 years or older. The primary outcome was COPD, defined according to the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) lung function criteria. FINDINGS: Between Dec 29, 2014, and Dec 31, 2015, 66 752 adults were recruited to the study population. The estimated standardised prevalence of COPD was 13·6% (95% CI 12·0–15·2). The prevalence of COPD differed significantly between men and women (19·0%, 95% CI 16·9–21·2 vs 8·1%, 6·8–9·3; p<0·0001), mainly because of a significant difference in smoking status between men and women (current smokers 58·2% vs 4·0%). The prevalence of COPD differed by geographic region, with the highest prevalence in southwest China (20·2%, 95% CI 14·7–25·8) and the lowest in central China (10·2%, 8·2–12·2). Among adults with COPD, 56·4% (95% CI 53·7–59·2) had mild disease (GOLD stage I), 36·3% (34·3–38·3) had moderate disease (GOLD stage II), 6·5% (5·5–7·4) had severe disease (GOLD stage III), and 0·9% (0·6–1·1) had very severe disease (GOLD stage IV). INTERPRETATION: In a large, nationally representative sample of adults aged 40 years or older, the estimated overall prevalence of COPD in China in 2014–15 was 13·6%, indicating that this disease has become a major public-health problem. Strategies aimed at prevention and treatment of COPD are needed urgently. FUNDING: Chinese Central Government, the Ministry of Science and Technology of The People's Republic of China, and the National Natural Science Foundation of China.
format Online
Article
Text
id pubmed-7185405
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71854052020-04-28 Chronic obstructive pulmonary disease in China: a nationwide prevalence study Fang, Liwen Gao, Pei Bao, Heling Tang, Xun Wang, Baohua Feng, Yajing Cong, Shu Juan, Juan Fan, Jing Lu, Ke Wang, Ning Hu, Yonghua Wang, Linhong Lancet Respir Med Articles BACKGROUND: Because of the rapid change in economic development and lifestyle in China, and the ageing population, concerns have grown that chronic obstructive pulmonary disease (COPD) could become epidemic. An up-to-date nationwide estimation of COPD prevalence in China is needed. METHODS: We did a cross-sectional survey of a nationally representative sample of individuals from mainland China aged 40 years or older. The primary outcome was COPD, defined according to the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) lung function criteria. FINDINGS: Between Dec 29, 2014, and Dec 31, 2015, 66 752 adults were recruited to the study population. The estimated standardised prevalence of COPD was 13·6% (95% CI 12·0–15·2). The prevalence of COPD differed significantly between men and women (19·0%, 95% CI 16·9–21·2 vs 8·1%, 6·8–9·3; p<0·0001), mainly because of a significant difference in smoking status between men and women (current smokers 58·2% vs 4·0%). The prevalence of COPD differed by geographic region, with the highest prevalence in southwest China (20·2%, 95% CI 14·7–25·8) and the lowest in central China (10·2%, 8·2–12·2). Among adults with COPD, 56·4% (95% CI 53·7–59·2) had mild disease (GOLD stage I), 36·3% (34·3–38·3) had moderate disease (GOLD stage II), 6·5% (5·5–7·4) had severe disease (GOLD stage III), and 0·9% (0·6–1·1) had very severe disease (GOLD stage IV). INTERPRETATION: In a large, nationally representative sample of adults aged 40 years or older, the estimated overall prevalence of COPD in China in 2014–15 was 13·6%, indicating that this disease has become a major public-health problem. Strategies aimed at prevention and treatment of COPD are needed urgently. FUNDING: Chinese Central Government, the Ministry of Science and Technology of The People's Republic of China, and the National Natural Science Foundation of China. Elsevier Ltd. 2018-06 2018-04-09 /pmc/articles/PMC7185405/ /pubmed/29650407 http://dx.doi.org/10.1016/S2213-2600(18)30103-6 Text en © 2018 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Articles
Fang, Liwen
Gao, Pei
Bao, Heling
Tang, Xun
Wang, Baohua
Feng, Yajing
Cong, Shu
Juan, Juan
Fan, Jing
Lu, Ke
Wang, Ning
Hu, Yonghua
Wang, Linhong
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
title Chronic obstructive pulmonary disease in China: a nationwide prevalence study
title_full Chronic obstructive pulmonary disease in China: a nationwide prevalence study
title_fullStr Chronic obstructive pulmonary disease in China: a nationwide prevalence study
title_full_unstemmed Chronic obstructive pulmonary disease in China: a nationwide prevalence study
title_short Chronic obstructive pulmonary disease in China: a nationwide prevalence study
title_sort chronic obstructive pulmonary disease in china: a nationwide prevalence study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185405/
https://www.ncbi.nlm.nih.gov/pubmed/29650407
http://dx.doi.org/10.1016/S2213-2600(18)30103-6
work_keys_str_mv AT fangliwen chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT gaopei chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT baoheling chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT tangxun chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT wangbaohua chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT fengyajing chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT congshu chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT juanjuan chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT fanjing chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT luke chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT wangning chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT huyonghua chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy
AT wanglinhong chronicobstructivepulmonarydiseaseinchinaanationwideprevalencestudy